Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANDISHORT: Short-duration therapy for uncomplicated candidemia
2024-514244-81-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2026
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of anidulafungin, micafungin, liposomal amphotericin b, caspofungin, voriconazole and 1 more in candidemia (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: All-cause mortality at Day 28. Planned start Mar 2026; status: authorised.
02
Drugs
anidulafunginmicafunginliposomal amphotericin bcaspofunginvoriconazole
03
Conditions
candidemia
Beyond the preview
Go deeper on 2024-514244-81-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514244-81-00.